The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma

Susanne Smolka, Julius Chapiro, Wilfred Manzano, John Treilhard, Eric Reiner, Yanhong Deng, Yan Zhao, Bernd Hamm, James S. Duncan, Bernhard Gebauer, Ming De Lin, Jean François Geschwind

Research output: Contribution to journalArticle

Abstract

Purpose To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. Materials and methods Each of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria. Results Percentage-based qEASL achieved significant separation in both therapy arms (p = 0.046 and p = 0.015). Response and Overall Survival showed similar association among treatment groups (p = 0.749). Conclusions Anti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalClinical Imaging
Volume46
DOIs
StatePublished - Nov 1 2017

Fingerprint

Hepatocellular Carcinoma
Liver
Neoplasms
Therapeutics
Survival
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. / Smolka, Susanne; Chapiro, Julius; Manzano, Wilfred; Treilhard, John; Reiner, Eric; Deng, Yanhong; Zhao, Yan; Hamm, Bernd; Duncan, James S.; Gebauer, Bernhard; Lin, Ming De; Geschwind, Jean François.

In: Clinical Imaging, Vol. 46, 01.11.2017, p. 1-7.

Research output: Contribution to journalArticle

Smolka, Susanne ; Chapiro, Julius ; Manzano, Wilfred ; Treilhard, John ; Reiner, Eric ; Deng, Yanhong ; Zhao, Yan ; Hamm, Bernd ; Duncan, James S. ; Gebauer, Bernhard ; Lin, Ming De ; Geschwind, Jean François. / The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. In: Clinical Imaging. 2017 ; Vol. 46. pp. 1-7.
@article{a9613b18efc8458582af2252055ffcfa,
title = "The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma",
abstract = "Purpose To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. Materials and methods Each of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria. Results Percentage-based qEASL achieved significant separation in both therapy arms (p = 0.046 and p = 0.015). Response and Overall Survival showed similar association among treatment groups (p = 0.749). Conclusions Anti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.",
author = "Susanne Smolka and Julius Chapiro and Wilfred Manzano and John Treilhard and Eric Reiner and Yanhong Deng and Yan Zhao and Bernd Hamm and Duncan, {James S.} and Bernhard Gebauer and Lin, {Ming De} and Geschwind, {Jean Fran{\cc}ois}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.clinimag.2017.05.007",
language = "English (US)",
volume = "46",
pages = "1--7",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma

AU - Smolka, Susanne

AU - Chapiro, Julius

AU - Manzano, Wilfred

AU - Treilhard, John

AU - Reiner, Eric

AU - Deng, Yanhong

AU - Zhao, Yan

AU - Hamm, Bernd

AU - Duncan, James S.

AU - Gebauer, Bernhard

AU - Lin, Ming De

AU - Geschwind, Jean François

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. Materials and methods Each of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria. Results Percentage-based qEASL achieved significant separation in both therapy arms (p = 0.046 and p = 0.015). Response and Overall Survival showed similar association among treatment groups (p = 0.749). Conclusions Anti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.

AB - Purpose To investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. Materials and methods Each of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria. Results Percentage-based qEASL achieved significant separation in both therapy arms (p = 0.046 and p = 0.015). Response and Overall Survival showed similar association among treatment groups (p = 0.749). Conclusions Anti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.

UR - http://www.scopus.com/inward/record.url?scp=85021396912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021396912&partnerID=8YFLogxK

U2 - 10.1016/j.clinimag.2017.05.007

DO - 10.1016/j.clinimag.2017.05.007

M3 - Article

VL - 46

SP - 1

EP - 7

JO - Clinical Imaging

JF - Clinical Imaging

SN - 0899-7071

ER -